Gene-targeted personalized medicine is over-hyped, with widespread use still 15 to 20 years away, says a leading group of scientists.

It’s hoped that the approach, called pharmacogenetics or pharmacogenomics, could improve treatment and reduce treatment side-effects.



A report by the UK’s Royal Society, however, says more research into the genetics of complex diseases, DNA testing, international guidelines and investment are needed before targeted therapies become widely available.



More here.